Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Overnight Urinary Cortisol creatinine ratio
研究概览
简要总结
The purpose of this study is to determine the effect of plastic spacers and breath actuated spacers on respirable drug delivery of combination steroid inhaler (Seretide/Advair) and whether electrostatic charge within plastic spacers has a clinically relevant impact on the inhaled steroid delivery.
详细描述
Conventional plastic spacers are bulky and can be influenced by electrostatic charge, which can reduce respirable dose delivery especially when used brand new "out of the box". Breath actuated integrated vortex spacer (Synchro-Breathe) is a compact palm sized antistatic device with a vortex chamber which is designed to be more patient friendly and free from the effects of electrostatic charge. The systemic bioavailability from the lung of inhaled fluticasone and salmeterol is dependent on respirable dose delivery, and hence the performance of inhaler devices can be quantified by measuring the degree of adrenal suppression and fall in serum potassium(K) as surrogates for delivered lung dose. This study attempts to compares the systemic bioavailability from the lung in real life conditions for Fluticasone/Salmeterol combination (measured in terms of relative adrenal suppression and fall in serum K) via the breath actuated Synchro-Breathe device, pMDI( Seretide Evohaler), and Aerochamber Plus & Volumatic spacer used brand new "out of the box" in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Volunteers
- •Male or female 18-65
- •Informed Consent
- •Ability to comply with the requirements of the protocol
排除标准
- •No respiratory disease
- •Recent respiratory tract infection (2 months).
- •Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
- •Any significant abnormal laboratory result as deemed by the investigators
- •Pregnancy, planned pregnancy or lactation
- •Known or suspected contra-indication to any of the IMP's
- •Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial
研究组 & 干预措施
Evohaler
干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)
Evohaler
干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)
Volumatic spacer
干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)
Volumatic spacer
干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)
Synchro-Breathe
干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)
Evohaler
干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)
Aerochamber Plus
干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)
Evohaler
干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)
Aerochamber Plus
干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)
Aerochamber Plus
干预措施: Seretide 250/placebo via Synchro-Breathe (Drug)
Synchro-Breathe
干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)
Synchro-Breathe
干预措施: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer (Drug)
Volumatic spacer
干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)
Volumatic spacer
干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)
Aerochamber Plus
干预措施: Seretide 250(8puffs) via Evohaler actuator (Drug)
Synchro-Breathe
干预措施: Seretide 250 (8 puffs)/placebo via Volumatic spacer (Drug)
结局指标
主要结局
Overnight Urinary Cortisol creatinine ratio
时间窗: within 24 hours after study drug inhalation
This outcome measure evaluates the amount of cortisol being suppressed after inhaled steroid administration. This helps to assess the systemic effect of steroid inhalation and therefore the propensity for adrenal suppression which is a noted adverse effect with high dose inhaled steroids
次要结局
- Serum Potassium(60 minutes post treatment)
研究者
Brian J Lipworth
Professor (Clinical) Airway allergy and COPD
University of Dundee
